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The productivity decline in drug discovery and development ismainly caused by two factors;
higher regulatory hurdles and low-hanging fruits being all picked. In addition, the recent
target-based approach is thought to be increasing the price of innovation. Although target-
based approach hadmany successes, a postreductionismmethod, which is systems biology,
is on the rise. In this review,we discuss the foundations of two distinct approaches in ﬁnding
a new drug.rug development
ntegrative
eductionism
ystems biology
© 2014 Korea Institute of Oriental Medicine. Published by Elsevier. This is an open access
article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
experimental procedures that are required by today’s drug dis-arget-based approach
. Introduction
he pharmaceutical industry is currently facing unparalleled
hallenges to develop innovative new drugs. Although the
nnual number of new drugs approved by the Food and Drug
dministration (FDA) has not changed much, research and
evelopment (R&D) investment per drug is escalating at a
arked rate. The estimated cost of developing a new drug is
pproximately $1 billion.1–3 This phenomenon, the increase
n R&D investment without the corresponding increase in the
umber of new drug approval, is known as the “innovation
ap.”4 After the Thalidomide and Vioxx incidents, regula-
ory bodies throughout the world are demanding more safety
ata, which in turn increases the development costs. Lack
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http://creativecommons.org/licenses/by-nc-nd/4.0/).of efﬁcacy is another important factor that contributes to
the high attrition rate. Nowadays, even me-too drugs must
provide more beneﬁt than the conventional therapeutics to
be approved. Both safety and efﬁcacy hurdles are responsi-
ble for the rising cost in drug discovery and development. To
minimize the risk in internal R&D, pharmaceutical companies
began to rely more on outside innovation. The effectiveness
of big pharmaceutical companies’ (big pharmas) R&D exter-
nalization strategies are being questioned as more and more
assets are put into early-stage pipelines.Many state-of-the-art
technologies such as high-throughput screening are speedingKorea Finance Corporation, 22 Eunhaeng-Ro, Yeongdeungpo-Gu,
covery and development. However, applying new technologies
anddevices alsomeans increased costs. From1950 to 2008, the
FDA approved 1222 new drugs new molecular entities or new
vier. This is an open access article under the CC BY-NC-ND license
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biological entities (NMEs or NBEs). Even though the amount of
investment per drug has increased exponentially, the annual
number of approvals has remained unaffected.5 There are >
4000 companies undergoing some forms of drug discovery and
development.However, only 261 companieshave succeeded in
registering a new drug since 1950. In the United States alone,
> 50,000 doctoral and postdoctoral researchers are conduct-
ing basic, translational, and clinical research. These research
ventures spend > $90 billion annually. The National Institute
of Health alone provides $33 billion into life sciences. Lazonick
andTulum6 explained that the strength of theU.S. biopharma-
ceutical industry originated on three factors: large National
Institute of Health funding, strong appetite for biotechnology
initial public offering, and vibrant venture capital investment.
Indisputably, the pharmaceutical industry contributed greatly
to improve health conditions and longevity. Nevertheless,
the time is ripe to discuss the mounting problems in drug
discovery and development approaches to push the pharma-
ceutical industry into the next level. So, two questions arise.
Is target-based approach the reason behind the current fall in
productivity? Should the concept of systems biology replace
the reductionists’ view to succeed in drug discovery and devel-
opment?
2. Target-based approach and systems
biology
The purpose of drug design is to ﬁnd the optimal structure
that possesses high speciﬁcity around the target and inter-
feres less with other sites to decrease the likelihood of side
effects. Screening is very expensive, thus contributing heavily
to drug development cost. In the past few decades, knowledge
in science has leaped forward dramatically. With the help of
reductionist methodologies, our understanding of the human
body and diseases has increased enormously. Reductionism,
as preached by Ernest Nagel, considers that all higher-level
theories can be reduced to some basal-level theories.7,8 This
is in agreement withMarshall Nirenberg’s dictum that science
progress bestwhen there are simple assays capable of generat-
ing large data sets rapidly.9 In short, gene to protein to function
is the central tenet in modern biology. Because most drug
action sites are proteins, targeting protein became the founda-
tion of modern drug discovery and development. Meanwhile,
the so-called low-hanging fruit is now picked, which suggests
that more effort, whether ﬁnancial or scientiﬁc, is needed to
develop a new drug. Therefore, redeﬁning the drug discovery
and development is a grand challenge for the pharmaceu-
tical industry. In order to endure the upcoming challenges,
for example, blockbuster patent cliff and price containment
pressures from the payers, a more integrative approach must
be implemented.
Until the 1990s, drug discovery and development was
largely based on a phenotypic approach or observation-based
approach. However, the accumulation of knowledge in bio-
chemistry and molecular biology led to a shift toward the
target-based approach. The appearance of recombinant DNA
and low-cost fast protein liquid chromatography facilitated
this change.10 At that time, the phenotypic approach was
challenged by many scientists just as target-based approachIntegr Med Res ( 2 0 1 4 ) 211–216
is being scrutinized at present. Even in Phase 1 of the clin-
ical trial, the phenotypic approach was unable to provide
the mechanisms of the action of a drug. Lack of knowl-
edge was particularly risky when tested on human volunteers
for various reasons (e.g., toxicity). Therefore, drug-developing
chemists and biologists in the 1990s mostly welcomed the
transformation into a target-based approach, which was
thought to be more predictable and science-driven. Two
decades of experience shows that the target-based approach
is failing to boost the productivity in drug discovery and devel-
opment. Selected targets were often not druggable and with
poor disease linkage, leading to either high toxicity or poor
efﬁcacy. The off-target effect of a drugwasmuchmore difﬁcult
to predict in comparison to the phenotypic approach. Because
the whole industry was using similar compound libraries for
druggable targets, the diversity of pharmaceutical companies’
portfolio has been damaged. This led to intense competition,
where speed of clinical trials and marketing were the main
attributes in determining the ﬁrst-in-class or best-in-class.
The decline in productivity in the past two decades coin-
cided with the introduction of target-based approaches.11
However, the target-based approach is not the only expla-
nation for this decline in productivity because innovative
therapeutics such as monoclonal antibodies, antibody-drug
conjugates (ADCs), and Gleevec had appeared. However, once
the target-based approach has become a standard in all
disease areas, it may lead to a predicament. The debate
on physiology-based approach and target-based approach is
still ongoing. But both physiology-based and target-based
approaches should be taken into account to have a better
chance of controlling the so-called difﬁcult diseases. A holistic
view or integrative approach is therefore the key to blend the
two contradictory, yet complementary, methods (Fig. 1).12
Consequently, no onepharmaceutical company canhandle
the entire spectrumof science, not tomention the vast disease
areas. This is why collaborations between the industry and
universities are becoming a prerequisite. To keep going in this
challenging era, pharmaceutical companies need to innovate
constantly with the outside world. Open innovation, which
was ﬁrst coined by Henry Chesbrough,13 is the most talked-
about termwhen discussing future research and development
(R&D). More and more pharmaceutical companies are imple-
menting the concept of open innovation in their business
model. Although the limits of target-based approach are well
established, it still remains as the gold standard to push the
candidatemolecule all theway to Phase 3. This is also the case
in government grants or when submitting a research paper.
Prior to the rise of molecular biology, phenotypic screening
was the norm in ﬁnding a new candidate molecule. At that
time, the mode of action was not fully elucidated. Thus, the
majority of drugs entered clinical trials without the under-
standing right down to amolecular level. A single target drug is
verydesirable theoretically in termsof both safety andefﬁcacy.
It will be straightforward to predict and control the strength of
action. Alas, each drug on average acts on at least ﬁve different
targets, causing mild to severe side effects. In reality, a drug
that acts via a single target is very difﬁcult to ﬁnd. With the
advent of information technology, the concept of big data is
infused into the early stage screening process. Even with the
today’s gigantic computing power, it is not feasible to examine
K. Earm and Y.E. Earm/Integrative approach in the era of failing drug discovery and development 213
Fig. 1 – Impact of systems biology in drug discovery and development. Various –omics can be useful to improve
target-based drug discovery pathways, especially in ﬁnding novel leads and targets.
Note. From “Systems biology in drug discovery and development,” by E. Berg, 2014, Drug Discov Today, 19, p. 113–125.
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rug interactions at all levels. Unknown targets remain to be
iscovered, and the accuracy of screening process is far from
atisfactory. In terms of cost, screening, althoughwidely used,
ecome inefﬁcient at certain points.
. Interdisciplinary research becoming the
ey issue in collaboration
ntil recently, pharmaceutical companies preferred develop-
ng drugs in a closed system. Information and knowledge
enerated within the company was tightly concealed. This
endency began to change since the early 1980s when com-
lex biologicals started to appear in the market. Biologicals
ad a signiﬁcant impact on the way things were done in the
harmaceutical industry. After Genentech, numerous biotech
entures emerged with the latest technologies. Recombinant
NA, at that time was very new to traditional pharma-
eutical companies. Simultaneously, codevelopment between
cademia and industry became a trend in diversifying the
ipeline. Numerous new molecular entities (and new biologi-
al entities) came from universities. If a promising candidate
or technology) was discovered, building a venture was a
ommon path to take. Big pharmas monitor and work with
niversities and small biotechnology companies for licensing
pportunities. In academia–industry collaborations, conﬂicts
f interests may occur owing to their disparate priorities.
cademic scientists’ main role in the university is to dissemi-
ate knowledge throughpublications. Quality (and sometimes
uantity) publication puts them in a good position to apply for
grant. Conversely, industry players want to keep interesting
ndings away from their competitors. That is, ﬁling a patenty Elsevier. All rights reserved, Reproduced with permission.
insteadof publication tomaximize the chanceof a commercial
breakthrough.
There is a huge chasm between universities and pharma-
ceutical companies, but they are learning to work together.
From pharmaceutical companies’ point of view, merger and
acquisitions (M&A), licensing, and academic collaboration are
vital in strengthening the pipelines. As mentioned previ-
ously, low-hanging fruits are no longer available; this is why
the industry keeps on tapping universities for novel ideas.
Academia, by contrast, is always short on research grants,
so funding from the industry is considered a good alter-
native. Although publication is the number one choice for
academics, they are beginning to accept the slight delay (6
months or after Phase 2 proof-of-concept stage) in publication
that is requested by pharmaceutical companies. For startups,
geographical proximity with world-renowned universities is
very important in nurturing their innovative capabilities. The
transfer of tacit knowledge between organizations within bio-
clusters is possibly the most notable beneﬁt of being grouped
together.14 In theUnited States, there aremany successful bio-
clusters such as San Diego, CA, and Boston, MA. Many tried to
reproduce the innovative environment in those bioclusters,
but only the hardware (buildings, research facilities, etc.) was
implemented with the absence of software (scientists, collab-
orative atmosphere, etc.). Bioclusters will no doubt continue
to be the birthplace of innovative products in the pharma-
ceutical industry. Thus, policy makers should concentrate on
the innovative ecosystem, especially the software segment,
to build a sustainable pharmaceutical industry. Furthermore,
clustering of various participants in industry is also suitable
for practicing the integrative approach in drug discovery and
development.
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4. A new hype needed?
TheHumanGenome Project at the turn of the century resulted
in ahypewhere newly formedbiotechnology ventures beneﬁt-
ted from the constant inﬂow of investments. In the end, high
expectations led to a bubble burst. Most industry observers
consider hype as detrimental for both investors and compa-
nies. But in terms of focusing resources, for example, policy
makers, analysts, and the industry itself, hype has somemerit
in advancing the technological development forward.15 In
addition to this genomic revolution, combinatory chemistry
and ultrahigh-throughput technologies increased the expec-
tations of the public.16 About 8000 potential drug targets
had been identiﬁed, of which only 218 are currently used as
drug targets. And 100 of those are undergoing clinical tri-
als, meaning that there are plenty of druggable targets to
lessen the unmet medical needs. Unfortunately, drug dis-
covery and development is not just driven by scientiﬁc or
philanthropic motives. In order to attract pharmaceutical
companies’ attention, corresponding targets or diseases must
have strong ﬁnancial incentives. The pharmaceutical indus-
try has been criticized for investing rather heavily on me-too
drugs. Rare diseases and tropical diseases hitherto have been
largely neglected by major pharmaceutical companies owing
to their low market potential. In the case of rare diseases,
the government and payers are willing to accept high prices,
giving pharmaceutical companies a good reason to develop a
drug.
Big pharma is currently under heavy pressure from their
shareholders to innovate with much less resources and time.
With the recent blockbuster patent expiry, major pharma-
ceutical companies are under a restructuring process. Many
R&D centers are closed and research staff are being laid off.
From small biotechnology ﬁrms to big pharma, rising costs
in drug development is impacting their business model. The
open innovation that is disseminated throughout the industry
will no doubt enhance the effectiveness of the drug discovery
and development process.17. It can be argued that the afore-
mentioned reductionists’ method, although very pragmatic
and scientiﬁcally strong, will not be sufﬁcient to confront
the mounting problems. Application of big data technologies
in screening processes seems inevitable but when applied
to a target-based approach, it might further increase the
drug development cost with little advantage. There are many
examples where a single-target drug failed to generate the
required safety and efﬁcacy in the late phase. Late failures
signiﬁcantly affect the future prospects of a company. The sit-
uation gets worse when the exact mechanism of a disease
is far from complete. Alzheimer’s disease is a classic exam-
ple where the wrong biomarker resulted in a staggering cost,
only to fail in the late clinical stage. Our understandings of
Alzheimer’s disease is at an infant stage, hence the typical
target-based approach can be misguiding. Yet, the combina-
tion of the right target and highly speciﬁc drug candidate
can be a very powerful tool. To have any chance of devel-
oping a novel therapy in a difﬁcult disease area, all insights
from both the reductionist and nonreductionist approaches
are required. The importance of interdisciplinary research is
stressed at all times, but never between molecular biologistsIntegr Med Res ( 2 0 1 4 ) 211–216
and systems biologists. If that were to occur, a great synergy
is expected.
5. Postreductionism era
. . .each part of Nature agrees with the whole, and theman-
ner in which it is associated with the remaining parts. . ..
By the association of parts, then, I merely mean that the
laws or nature of one part adapt themselves to the laws
or nature of another part, so as to cause the least possible
inconsistency. . ..
B. Spinoza
Although the reductionist approach — identifying drugs
that activate or inhibit speciﬁc targets — dominated the way
drugs were developed, the complexity of biology is calling
for more action. It is clear that the biological function or
malfunction cannot be manipulated by a single protein or
gene.18 Moreover, as Frank Sams-Dodd put it,19 by reducing
something to its components, we lose understanding of how
the components interact to produce function and why they
change as they do. Systems biology, by contrast, is providing
a more holistic view in medicine. Interdisciplinary research
is the key aspect of systems biology where mathematicians,
engineers, physicists, computer scientists, and biologists are
brought together.20 In experiments, simplicity helps, but it
may not directly represent the physiology in real-life situa-
tions. Many clinical trials fail even with positive in vitro and
in vivo studies, because the complexity and variables in clinical
trials are much greater. Therefore, the dynamic picture of the
disease, mechanisms, and drug interactions is a prerequisite
to decrease the dire attrition rates. Various technologies that
were developed in areas of next-generation sequencing, tran-
scriptomics, metabolomics, and proteomics can be of value to
systems biology. Quite often, systems biology is perceived as
managing Big Data obtained from combinations of “–omics.”
Understanding life is not just about adding its components
together. Noble’s computational model of the heart gives a
perfect example of a multiscale approach that includes bio-
chemistry, anatomy, and functional level parameters. Systems
biology entails investigating phenomena in terms of how the
objects are related, rather than what their compositions are.21
The most noticeable movement in modern pharmaceuti-
cal industry is opening up large databases in order to facilitate
drug development in areas of unmet medical needs. Univer-
sities, big pharmas, the FDA, and many others are disclosing
their own database to be assessed for research use. As a result,
a tremendous amount of data is available, but without the
advanced computational tools, interpretation of these data
would be impractical. The database on the bioavailability of
chemicals is increasing at a substantial rate. The number of
bioassay data on PubChem has increased from 800 records to
500,000 records in a period of 3 years. Currently, data from
in vitro target binding assays and chemical perturbation exper-
iments with associated gene expression proﬁles is routinely
deposited in public databases.22 There were many efforts
from the commercial and academic institutions to apply sys-
tems biology into drug discovery and development platforms
(Table 1).23
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Table 1 – Examples of organizations that incorporate systems biology approaches for drug discovery
Name Approach
Bioseek
(http://www.bioseekinc.com)
Uses systems biology approach to study primary human cell disease models
Beyond Genomics
(http://www.beyondgenomics.com)
Technology platform facilitates analysis of clinically relevant samples and
integrates data from the gene, protein, metabolite, and clinic for biomarker and
target identiﬁcation
Cellnomica
(http://www.cellnomica.com)
Conducts novel multicellular modeling in drug discovery and development
Cellzome
(http://www.cellzome.com)
Proprietary functional proteomics technology for therapeutic target discovery,
validation, and drug development
Department of Energy’s Genomes to Life initiative
(http://doegenomestolife.org/overview/pdf)
The Genomes to Life roadmap (plans to design and exploit new high-throughput
strategies to obtain a blueprint of how living systems function)
Eli Lilly Center for Systems Biology
(http://www.lilly.com)
Focuses on integration of proteomic and genomic technologies to support drug
discovery efforts
Entelos
(http://www.entelos.com)
Biosimulation company that develops computer models of human disease using
novel PhysioLab technology
Institute for Systems Biology
(http://www.systemsbiology.org)
Broad based program. Uses systems biology to investigate the complex interaction
of biological elements that form hierarchical networks that deﬁne systems
Kitano Symbiotic Systems Project
(http://www.symbio.jst.go.jp)
The project aims to understand and design biological systems, thus creating a new
paradigm in biology focuses on model organisms including fruit ﬂy, yeast, and
bacteria
Physiome Sciences
(http://www.physiome.com)
Biosimulation company that has created and develops integrated software platform
for computer-based biological models applicable to drug discovery
SurroMed
(http://www.surromed.com)
Develops and implements biological marker discovery platform to proﬁle
biochemical components in blood and other biological samples
Note. From “Advancing drug discovery through systems biology,” by E. Davidov et al., 2003, Drug Discov Today, 8, p. 175–183. Copyright 2014, Korea
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Another interesting development in the science of drug
iscovery and development is the rise of chemical biology.
nstead of one-protein–one-ligand model, chemical biology
ries to deﬁne a drug promiscuity24 and look for a possible
ndication. This multitarget approach is thought to be more
ensible because, asDenisNoble25 expounded, no simple, one-
o-one correspondence between genes and phenotypes can
e made. Throughout human history, herbal medicines were
eveloped by long experience. Korean traditional medicine
ims to understand the whole, which shares the similar con-
ept of systems biology. There are many attempts to turn
erbal medicine products into a Western-style drug, where
ultitarget approach also became the preferred tactic.
In the past century, reductionists have divided medicine
nto small bits. In this coming era, it is an opportune time to
ntegrate the scattered blocks of our knowledge. The mecha-
isms and organizations are the key to understanding living
hings and consequently to develop a new drug. Although
ery sensible in theory, systems biology is very difﬁcult to
pply in clinical trials and even in actual medical practice. In
eart failure, for example, reductionists will view the prob-
em in a single gene, a single target, or a single drug molecule,
hich illustrates the current inertia in medicine. For systems
iologist, the problem gets more complicated and subjective.
here would be tons of data to explore and connect the puzzleproduced with permission.
pieces together to ﬁnd the right treatment. The multitarget
approach is the proposed choice at this point, but reduction-
ist will argue that this approach is simply adding two or more
target-based approaches in the hopes of attaining beneﬁcial
outcomes. Accordingly, systems biology holds a difﬁcult task
in itself to embrace the disciplines of reductionism and add
some philosophy to become the next driving force in science
and industry.
6. Conclusion
Biological science in the 20th century focused on breaking
things down into microscopic or more manageable pieces in
order to unlock the complexity of bodily function. Just as the
environment inﬂuences the characteristics of organisms, an
innovative ecosystem also has a critical role in drug discovery
and development. The limitation of target-based approaches
has been addressed, but the most commercially successful
drugs are, in fact, still developed using such methodologies.
Therefore, a shift from reductionism to nonreductionism is
difﬁcult to envisage within the industry in the near future.
Such scientiﬁc endeavors require vision, and patience, which
counterbalances the shareholders’ interests: a short-termgain
in stock markets. To begin with, the paradigm shift to a
r216
more holistic perspectivemust come from university research
groups. However, for this development to occur, science-
funding organizations should be well informed about the
pros and cons of systems biology. Interdisciplinary research is
happening most frequently between university departments.
For innovative ecosystem to be implemented, collaboration
should be formed between all sorts of stakeholders. It is essen-
tial to note that universities, public organizations, venture
capitals, consulting ﬁrms, and other groups are all contribut-
ing to bioclusters, where most licensing deals, investments,
and collaborations are occurring. For academics, the integra-
tive approach is synonymously used as systems biology. On
the industry level, the integrative approach could also rep-
resent the blending of the elements of various stakeholders’
view together for better results. Systems biology is regarded as
a postgenome technology, together with bioinformatics that
will provide new solutions to various impediments in the
pharmaceutical industry. Whether the recent rise in systems
biology could be the next driving force in drug discovery and
development remains to be seen. Unlike the Human Genome
Project, systems biology is less likely to result in an invest-
ment hype; rather, it is apt to initiate a change at the very
starting point: the basic science. Therefore, the change will be
slower but in the long run, the impact on drug discovery and
developmentwould be substantial. Urgent agenda is not about
speeding things up but rather, seeing things in an integrative
manner to unravel the mystery of life. Nonetheless, advances
in technologies that reduce cost and time for screening proce-
dures, although insufﬁcient to reverse the current slowdown
of drug discovery and development, should not be underval-
ued. Tomorrow’s drug discovery and development is more in
need of a philosophy instead of incrementally improved tech-
nologies. Paul Janssen26 often described drug discovery and
development as an orchestra. For a successful paradigm shift,
whatwe needmost is probably the conductor of science bring-
ing together both reductionists and systemic biologists.
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